EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a novel ultrasound-mediated technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT) in Norway. The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various applications, including oncology, neurological conditions, and gene therapy. The company's ACT platform is under Phase 2 clinical trial for the treatment of pancreatic disease; Phase I clinical trial for treatment of liver metastases; and pre-clinical studies for glioblastoma, and immunotherapy diseases, as well as CNS diseases and gene therapy. It has a collaboration with GE Healthcare. The company was formerly known as Phoenix Solutions AS. EXACT Therapeutics AS was founded in 2012 and is based in Oslo, Norway.
Frequently asked questions
What sector does EXACT THERAP. AS NK 0004 (56F) operate in?
EXACT THERAP. AS NK 0004 belongs to the Healthcare sector and operates in the Biotechnology industry.
What is EXACT THERAP. AS NK 0004 (56F) current stock price?
As of the latest data, EXACT THERAP. AS NK 0004 stock price is €0.03, with a previous close of €0.03.
What is EXACT THERAP. AS NK 0004 (56F) current market capitalization?
EXACT THERAP. AS NK 0004 market cap is approximately 3.29 million.
What is EXACT THERAP. AS NK 0004 (56F) Earnings Per Share (EPS)?
The trailing EPS is -€0.13.
Does EXACT THERAP. AS NK 0004 (56F) pay dividends?
No. EXACT THERAP. AS NK 0004 does not pay a dividend.
What is EXACT THERAP. AS NK 0004 (56F) beta (volatility) score?
EXACT THERAP. AS NK 0004 has a beta of 0.073, indicating lower volatility than the overall market.
